CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Performance-Based Restricted Stock Units (PSUs)	Class A Common Stock	Class A Common Stock Performance-Based Restricted Stock Units (PSUs)	Additional Paid-In Capital	Additional Paid-In Capital Performance-Based Restricted Stock Units (PSUs)	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2022	0
Series A preferred stock , Beginning balance at Dec. 31, 2022	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of series A preferred stock, net of issuance costs (in shares)	175,000
Issuance of series A preferred stock, net of issuance costs	$ 168,000
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 4,829
Series A preferred stock , Ending balance (in shares) at Jun. 30, 2023	175,000
Series A preferred stock , Ending balance at Jun. 30, 2023	$ 172,829
Beginning balance (in shares) at Dec. 31, 2022			101,501,000
Beginning balance at Dec. 31, 2022	859,417		$ 1,015		$ 1,486,857		$ (1,178)	$ (606,154)	$ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	19,676				19,676
Exercise of stock options (in shares)			776,000
Exercise of stock options	4,654		$ 8		4,646
Restricted stock units vested, net of shares withheld for taxes (in shares)			492,000
Restricted stock units vested, net of shares withheld for taxes	(8,770)		$ 4		(8,774)
Stock units vested, net of shares withheld for taxes (in shares)			760,000	202,000
Stock units vested, net of shares withheld for taxes	0	$ (3,975)	$ 8	$ 2	(8)	$ (3,977)
Shares issued for acquisition (in shares)			8,475,000
Shares issued for acquisition	261,271		$ 85		261,186
Class A common stock issued for payment of earn-outs (in shares)			877,000
Class A common stock issued for payment of earn-outs	28,551		$ 9		28,542
Foreign currency translation adjustment	64						64
Net loss attributable to common shareholders of Evolent Health, Inc.	(67,669)				(13,364)			(54,305)
Ending balance (in shares) at Jun. 30, 2023			113,083,000
Ending balance at Jun. 30, 2023	$ 1,093,219		$ 1,131		1,774,784		(1,114)	(660,459)	(21,123)
Series A preferred stock , beginning balance (in shares) at Mar. 31, 2023	175,000
Series A preferred stock , Beginning balance at Mar. 31, 2023	$ 170,625
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 2,204
Series A preferred stock , Ending balance (in shares) at Jun. 30, 2023	175,000
Series A preferred stock , Ending balance at Jun. 30, 2023	$ 172,829
Beginning balance (in shares) at Mar. 31, 2023			112,552,000
Beginning balance at Mar. 31, 2023	1,121,743		$ 1,125		1,768,999		(1,122)	(626,136)	(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	8,966				8,966
Exercise of stock options (in shares)			446,000
Exercise of stock options	3,073		$ 5		3,068
Restricted stock units vested, net of shares withheld for taxes (in shares)			58,000
Restricted stock units vested, net of shares withheld for taxes	(138)				(138)
Class A common stock issued for payment of earn-outs (in shares)			27,000
Class A common stock issued for payment of earn-outs	978		$ 1		977
Foreign currency translation adjustment	8						8
Net loss attributable to common shareholders of Evolent Health, Inc.	(41,411)				(7,088)			(34,323)
Ending balance (in shares) at Jun. 30, 2023			113,083,000
Ending balance at Jun. 30, 2023	$ 1,093,219		$ 1,131		1,774,784		(1,114)	(660,459)	(21,123)
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2023	175,000
Series A preferred stock , Beginning balance at Dec. 31, 2023	$ 178,427
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 5,779
Series A preferred stock , Ending balance (in shares) at Jun. 30, 2024	175,000
Series A preferred stock , Ending balance at Jun. 30, 2024	$ 184,206
Beginning balance (in shares) at Dec. 31, 2023	115,424,833		115,425,000
Beginning balance at Dec. 31, 2023	$ 1,067,701		$ 1,154		1,808,121		(1,257)	(719,194)	(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	31,445				31,445
Exercise of stock options (in shares)			101,000
Exercise of stock options	1,119		$ 1		1,118
Restricted stock units vested, net of shares withheld for taxes (in shares)			531,000
Restricted stock units vested, net of shares withheld for taxes	(10,134)		$ 6		(10,140)
Stock units vested, net of shares withheld for taxes (in shares)				205,000
Stock units vested, net of shares withheld for taxes				$ 2		$ (4,566)
Class A common stock issued for payment of earn-outs	(4,564)
Foreign currency translation adjustment	(98)						(98)
Net loss attributable to common shareholders of Evolent Health, Inc.	$ (31,608)				(15,924)			(15,684)
Ending balance (in shares) at Jun. 30, 2024	116,261,854		116,262,000
Ending balance at Jun. 30, 2024	$ 1,053,861		$ 1,163		1,810,054		(1,355)	(734,878)	(21,123)
Series A preferred stock , beginning balance (in shares) at Mar. 31, 2024	175,000
Series A preferred stock , Beginning balance at Mar. 31, 2024	$ 181,294
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 2,912
Series A preferred stock , Ending balance (in shares) at Jun. 30, 2024	175,000
Series A preferred stock , Ending balance at Jun. 30, 2024	$ 184,206
Beginning balance (in shares) at Mar. 31, 2024			116,195,000
Beginning balance at Mar. 31, 2024	1,047,936		$ 1,162		1,805,679		(1,308)	(736,474)	(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	12,659				12,659
Exercise of stock options (in shares)			5,000
Exercise of stock options	60				60
Restricted stock units vested, net of shares withheld for taxes (in shares)			62,000
Restricted stock units vested, net of shares withheld for taxes	(364)		$ 1		(365)
Foreign currency translation adjustment	(47)						(47)
Net loss attributable to common shareholders of Evolent Health, Inc.	$ (6,383)				(7,979)			1,596
Ending balance (in shares) at Jun. 30, 2024	116,261,854		116,262,000
Ending balance at Jun. 30, 2024	$ 1,053,861		$ 1,163		$ 1,810,054		$ (1,355)	$ (734,878)	$ (21,123)